Table 1.
Phenotypes of patients with WNT1 mutations at baseline
Patient No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sillence classification | III | III | III | III | IV | III | IV | IV | IV | III | IV | III | EOOP | EOOP | EOOP | EOOP |
Sex | F | M | F | M | M | M | M | M | M | M | M | M | F | F | M | M |
Family history | No | No | No | No | No | No | No | No | No | No | No | No | Yes | Yes | No | No |
Consanguineous family | No | No | Yes | No | No | No | No | No | No | No | No | No | No | No | Yes | No |
Age at first diagnosis, y | 1.8 | 4.0 | 9.0 | 6.5 | 2.5 | 15.0 | 11.0 | 10.8 | 12.4 | 24.0 | 16.0 | 1.5 | 7.3 | 32.0 | 38.0 | 47.0 |
Age at first fracture, y | 0 | 3 d | 9 d | 2 mo | 10 mo | 16 mo | 2 | 3 | 8 | 10 | 13 | 0.5 | 3 | 6 | 27 | 47 |
Peripheral fracture, times | 8 | 7 | 25 | 10 | 2 | 2 | 2 | 1 | 6 | 8 | 1 | 4 | 4 | 5 | 0a | 0a |
Multiple vertebral fractures | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes |
Scoliosis | No | No | Yes | Yes | No | Yes | No | No | No | Yes | No | No | No | No | Yes | No |
Limb deformities | Yes | Yes | Yes | Yes | No | No | No | No | No | Yes | No | Yes | No | No | No | No |
Ptosis | Yes | No | No | Yes | No | No | No | No | No | No | No | Yes | No | No | No | No |
Joint hypermobility | No | No | Yes | No | No | No | No | Yes | No | No | No | No | No | No | No | No |
Blue sclera | Yes | Yes | Yes | No | No | Yes | No | Yes | Yes | No | No | No | No | No | No | No |
Dentinogenesis imperfecta | No | No | Yes | No | No | No | No | No | No | No | No | No | No | No | No | No |
Intellectual disability | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | Yes |
Height, Z score | −3.5 | −2.2 | −9.3 | −1.6 | 0.1 | −2.3 | −1.7 | −0.2 | −0.8 | −3.0 | −0.3 | −1.4 | −0.5 | 1.2 | −1.5 | −1.1 |
Weight, Z score | −0.7 | −1.8 | −7.1 | −0.4 | −1.0 | −6.4 | 0.5 | 1.5 | 2.4 | −0.9 | 0.3 | 0.6 | 0.7 | −0.8 | −1.4 | 1.3 |
LS BMD Z score | −4.2 | −7.9 | −6.4 | −0.5 | −4.2 | −6.4 | −3.6 | −4.2 | −3.8 | −4.4 | −2.5 | −8.5 | −2.7 | −3.0 | −4.0 | −2.6 |
FN BMD Z score | −5.6 | −1.9 | −7.4 | NA | −5.2 | −4.9 | −4.1 | −5.5 | −5.3 | −5.1 | −3.1 | −8.2 | −4.9 | −2.3 | −3.7 | −2.6 |
ALP, U/L | 198 | 289 | 238 | 264 | 218 | 207 | 257 | 321 | 276 | 90 | 145 | 377 | 173 | 41 | 76 | 69 |
β-CTX, ng/mL | 0.87 | 1.06 | NA | 1.11 | 1.05 | 0.70 | 1.06 | 1.30 | 0.50 | 0.20 | NA | 0.83 | 1.32 | 0.22 | 0.41 | 0.10 |
Patient 4, 5, and 16 had received antiresorptive treatment at baseline. FN BMD of the proximal femur in patient 4 was not unavailable because of the intramedullary nail.
Abbreviations: β-CTX, cross-linked C-telopeptide of type I collagen; ALP, alkaline phosphatase; BMD, bone mineral density; EEOP, early-onset osteoporosis; F, female; FN, femoral neck; LS, lumbar spine 2−4, M, male; NA, not available; TH, total hip.
Patients 15 and 16 had no peripheral fragility fractures and they went to the hospital because of back pain or low BMD identified at age 27 or 47 years.